The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability
Open accessAbstract
Individuals with hemizygous germline fumarate hydratase (FH) mutations are predisposed to renal cancer. These tumors predominantly exhibit functional inactivation of the remaining wild-type allele, implicating FH inactivation as a tumor-promoting event. Hypoxia-inducible factors are expressed in many cancers and are increased in clear cell renal carcinomas. Under normoxia, the HIFs are labile due to VHL-dependent proteasomal degradation, but stabilization occurs under hypoxia due to inactivation of HIF prolyl hydroxylase (HPH), which prevents HIF hydroxylation and VHL recognition. We demonstrate that FH inhibition, together with elevated intracellular fumarate, coincides with HIF upregulation. Further, we show that fumarate acts as a competitive inhibitor of HPH. These data delineate a novel fumarate-dependent pathway for regulating HPH activity and HIF protein levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to requiring 2-oxoglutarate as a cosubstrate, the HIF hydroxylases have been reported to be inhibited by citrate, isocitrate, succinate, fumarate, malate, oxaloacetate, and pyruvate (Dalgard et al., 2004; Hewitson et al., 2007; Isaacs et al., 2005; Koivunen et al., 2007a; Selak et al., 2005).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Isaacs et al., 2005
In the citing paper
“To date, the clearest evidence that metabolites modulate HIF signaling comes from cells that are genetically defective in fumarate hydratase (FH) (Isaacs et al., 2005) or succinate hydrogenase (SDH; subunits b, c, and d) (MacKenzie et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Isaacs et al., 2005
In the citing paper
“Similar to succinate, fumarate contributes to the inactivation of PHD, stabilizing HIF proteins to promote cell survival133”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [133]
In the citing paper
“For example, the HIF1α transcription factor accumulates in SDH and FH mutant tumors, presumably due to inhibition of the EglN prolyl hydroxylases (Dahia et al., 2005; Isaacs et al., 2005; Pollard et al., 2005, 2007; Selak et al., 2005).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Isaacs et al., 2005
In the citing paper
“A similar model of substrate-mediated PHD inhibition has been described (23, 37, 42) in which the loss of fumarate hydratase activity leads to the accumulation of fumarate, which also can inhibit PHD competitively.”
From Loss of the SdhB, but Not the SdhA, Subunit of Complex II Triggers Reactive Oxygen Species-Dependent Hypoxia-Inducible Factor Activation and Tumorigenesis (2008) · cites this paper as [23]
In the citing paper
“PHDs are inactive at low O2 and can be inactivated by the accumulation of TCA metabolites fumarate and succinate, which may occur from mutations in the tumor suppressor genes succinate dehydrogenase subunit B or fumarate hydratase (187, 334, 384).”
From Redox regulation of mitochondrial function (2012) · cites this paper as [187]
In the citing paper
“In addition to affecting the activity of chromatin-associated αKG-dependent dioxygenases, succinate and fumarate accumulation can also inhibit αKG-dependent prolyl hydroxylases, leading to stabilization of HIF-1 and concomitant activation of the HIF/hypoxia transcriptional program (184, 185).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [184]
In the citing paper
“High levels of succinate and fumarate can inhibit PHD2 activity through product-mediated inhibition of PHD function, leading to HIF-1α protein stabilization under normoxic (20% O2) conditions (100, 101).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [100]
In the citing paper
“Subsequent work confirmed that fumarate could inhibit PHD2 (Isaacs et al., 2005)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Isaacs et al., 2005
In the citing paper
“elevated levels of succinate or fumarate can inhibit PHD activity [65, 66]”
From Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function (2013) · cites this paper as [65]
In the citing paper
“Both succinate and fumarate are competitive PHD inhibitors, and the massive accumulation of these metabolites in cells lacking SDH or FH activity elicit a hypoxic response even under oxygen-replete condition (Isaacs et al., 2005; Selak et al., 2005).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Isaacs et al., 2005
In the citing paper
“Furthermore, both succinate and fumarate aberrantly increase the function of hypoxia inducible factors (HIFs).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Isaacs et al., 2005
In the citing paper
“In the case of D2HGA, about 50% of patients present with D2HGDH mutations, while the remaining half possess mutations in the Krebs cycle enzyme isocitrate dehydrogenase 2 (IDH2), which converts isocitrate to α-KG110.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [110]
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
Self-citationThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Self-citationHIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Self-citationA conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Cellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476
(1999) · PubMed · Cited by 2,204
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108 · cited 3×
“Succinate also upregulates HIF by inhibiting its proline hydroxylation (Selak et al., 2005), but in vitro enzyme kinetic analysis proves it to be a weaker antagonist of 2-OG, a finding in keeping with its reduced potency (relative to fumarate) in causing intracellular HIF accumulation in A549 cells.”
BackgroundInfluential
Cited by
Sorted by citations
Items 501–600 of 957
Bell, E. L., Klimova, T. A., & Chandel, N. S. (2007) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1655 · Cited by 30
Fisher, R. A., Larkin, J., & Swanton, C. (2011) · The EPMA Journal · doi:10.1007/s13167-011-0137-3 · Cited by 28
Bacterial fumarase and L-malic acid are evolutionary ancient components of the DNA damage response
Singer, E., Silas, Y., Ben‐Yehuda, S., & Pines, O. (2017) · eLife · doi:10.7554/elife.30927 · Cited by 28
Hypoxia and Hormone-Mediated Pathways Converge at the Histone Demethylase KDM4B in Cancer
Yang, J., Harris, A. L., & Davidoff, A. M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010240 · Cited by 30
Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas
Yoo, A., Tang, C., Zucker, M. R., Fitzgerald, K. N., DiNatale, R. G., Rappold, P. M., Weiss, K. L., Freeman, B., Lee, C., Schultz, N. D., et al. (2022) · European Urology Focus · doi:10.1016/j.euf.2021.12.002 · Cited by 29
Pheochromocytoma: Gasping for Air
Jochmanová, I., Zhuang, Z., & Pacák, K. (2015) · Hormones and Cancer · doi:10.1007/s12672-015-0231-4 · Cited by 30
Oxygen Sensing: A Common Crossroad in Cancer and Neurodegeneration
Quaegebeur, A., & Carmeliet, P. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_83 · Cited by 27
Kaluz, Š., Kaluzová, M., & Stanbridge, E. J. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21644 · Cited by 27
Lameirinhas, A., Miranda‐Gonçalves, V., Henrique, R., & Jerónimo, C. (2019) · Genes · doi:10.3390/genes10040264 · Cited by 28
Regulation of Renal Cell Carcinoma Cell Proliferation, Invasion and Metastasis by Connexin 32 Gene
Sato, H., Hagiwara, H., Ohde, Y., Senba, H., Virgona, N., & Yano, T. (2007) · The Journal of Membrane Biology · doi:10.1007/s00232-007-9020-5 · Cited by 28
Lin, A., Anderson, S. L., Minard, K. I., & McAlister-Henn, L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.266890 · Cited by 27
Yao, L., Barontini, M., Niederle, B., Jech, M., Pfragner, R., & Dahia, P. L. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2245 · Cited by 27
Metabolic Signaling in the Tumor Microenvironment
Clay, R., Li, K., & Jin, L. (2025) · Cancers · doi:10.3390/cancers17010155 · Cited by 31
HIF-Mediated Hypoxic Response is Missing in Severely Hypoxic Uterine Leiomyomas
Mayer, A., Hoeckel, M., von Wallbrunn, A., Horn, L., Wree, A., & Vaupel, P. W. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-1241-1_58 · Cited by 26
A Role for Saccharomyces cerevisiae Tpa1 Protein in Direct Alkylation Repair
Shivange, G., Kodipelli, N., Mohan, M., & Anindya, R. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.590216 · Cited by 26
Complex role of the HIF system in cardiovascular biology
Czibik, G. (2010) · Journal of Molecular Medicine · doi:10.1007/s00109-010-0646-x · Cited by 27
Branched-chain α-ketoacids aerobically activate HIF1α signalling in vascular cells
Xiao, W., Shrimali, N. M., Vigder, N., Oldham, W. M., Clish, C. B., He, H., Wong, S. J., Wertheim, B. M., Arons, E., Haigis, M. C., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01150-4 · Cited by 27
Kidney Cancer Pathology in the New Context of Targeted Therapy
Allory, Y., Culine, S., & TAILLE, A. D. L. (2011) · Pathobiology · doi:10.1159/000315543 · Cited by 25
Hypoxia in the intestine or solid tumors: A beneficial or deleterious alarm signal?
Shehade, H., Oldenhove, G., & Moser, M. (2014) · European Journal of Immunology · doi:10.1002/eji.201444719 · Cited by 26
Increased HIF1α in SDH and FH deficient tumors does not cause microsatellite instability
Lehtonen, H. J., Mäkinen, M. J., Kiuru, M. H., Laiho, P., Herva, R., van Minderhout, I. J. H. M., Hogendoorn, P. C. W., Cornelisse, C. J., Devilee, P., Launonen, V., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22819 · Cited by 26
Canonical and new generation anticancer drugs also target energy metabolism
Rodríguez‐Enríquez, S., Gallardo‐Pérez, J. C., Hernández‐Reséndiz, I., Marín‐Hernández, Á., Pacheco-Velázquez, S. C., López‐Ramírez, S. Y., Rumjanek, F. D., & Moreno‐Sánchez, R. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1246-2 · Cited by 24
The von Hippel–Lindau Tumor Suppressor Protein
Kaelin, W. G. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050527 · Cited by 24
Papillary Renal Cell Carcinoma: Current Progress and Future Directions
Twardowski, P. W., Mack, P. C., & Lara, P. N. (2013) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2013.11.013 · Cited by 24
Role of Oxygen in Cancer: Looking Beyond Hypoxia
López‐Lázaro, M. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009788451806 · Cited by 24
Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma
Karivedu, V., Jain, A., Eluvathingal, T. J., & Sidana, A. (2019) · Current Urology Reports · doi:10.1007/s11934-019-0932-2 · Cited by 25
Aleyasin, H., Karuppagounder, S. S., Kumar, A., Sleiman, S. F., Basso, M., Ma, T. C., Siddiq, A., Chinta, S. J., Brochier, C., Langley, B. C., et al. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5595 · Cited by 24
Fumarate integrates metabolism and immunity in diseases
Cheng, J., Xiao, Y., & Jiang, P. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.03.008 · Cited by 25
The impact of mitochondria on cancer treatment resistance
van der Merwe, M., van Niekerk, G., Fourie, C., du Plessis, M., & Engelbrecht, A. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00623-y · Cited by 24
Connections between metabolism and epigenetic modifications in cancer
Wang, G., & Han, J. J. (2021) · Medical Review · doi:10.1515/mr-2021-0015 · Cited by 27
The rise of viperin: the emerging role of viperin in cancer progression
Weinstein, A. G., Godet, I., & Gilkes, D. M. (2022) · Journal of Clinical Investigation · doi:10.1172/jci165907 · Cited by 24
The role of mutation of metabolism-related genes in genomic hypermethylation
Waterfall, J. J., Killian, J. K., & Meltzer, P. S. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.003 · Cited by 23
Genetically Modeled Mice with Mutations in Mitochondrial Metabolic Enzymes for the Study of Cancer
Piruat, J. I., & Millán‐Uclés, Á. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00200 · Cited by 21
Lago, C. U., Nowinski, S. M., Rundhaug, J. E., Pfeiffer, M. E., Kiguchi, K., Hirasaka, K., Yang, X., Abramson, E. M., Bratton, S. B., Rho, O., et al. (2012) · Oncogene · doi:10.1038/onc.2011.630 · Cited by 23
Impact of Genetics on the Diagnosis and Treatment of Renal Cancer
Singer, E. A., Bratslavsky, G., Middelton, L. A., Srinivasan, R., & Linehan, W. M. (2010) · Current Urology Reports · doi:10.1007/s11934-010-0156-y · Cited by 24
Self-citationHasumi, H., & Yao, M. (2018) · Cancer Science · doi:10.1111/cas.13503 · Cited by 24
Origin of renal cell carcinomas
Ayerbes, M. V., Gallego, G. A., Díaz‐Prado, S., Fonseca, P. J., Campelo, R. G., & Aparicio, L. M. A. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0276-8 · Cited by 23
HIF Prolyl-4-hydroxylase Interacting Proteins: Consequences for Drug Targeting
Wenger, R. H., Camenisch, G., Stiehl, D. P., & Katschinski, D. M. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789649411 · Cited by 21
Environmental and behavioral regulation of HIF-mitochondria crosstalk
Burtscher, J., Hohenauer, E., Burtscher, M., Millet, G. P., & Egg, M. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.06.015 · Cited by 27
Basic Mechanisms of Immunometabolites in Shaping the Immune Response
Ryan, D. G., Peace, C. G., & Hooftman, A. (2023) · Journal of Innate Immunity · doi:10.1159/000535452 · Cited by 22
Novel Mitochondria-targeted Drugs for Cancer Therapy
Fialová, J. L., Raudenská, M., Jakubek, M., Kejík, Z., Pavel Martasek, E., Babula, P., Matkowski, A., Filipenský, P., & Masařík, M. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666201118153242 · Cited by 22
Karuppagounder, S. S., Kumar, A., Shao, D. S., Zille, M., Bourassa, M. W., Caulfield, J. T., Alim, I., & Ratan, R. R. (2015) · Brain Research · doi:10.1016/j.brainres.2015.07.030 · Cited by 22
New Advances in the Genetics of Pheochromocytoma and Paraganglioma Syndromes
Gimenez‐Roqueplo, A. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.012 · Cited by 22
Metabolic sensors and their interplay with cell signalling and transcription
Krejčı́, A. (2012) · Biochemical Society Transactions · doi:10.1042/bst20110767 · Cited by 23
Bai, Y., Liu, Y., Qu, A., Wang, J., Zhao, J., Ke, Q., Chen, X., Pu, F., Wu, L., Xu, P., et al. (2022) · Aquaculture · doi:10.1016/j.aquaculture.2022.739104 · Cited by 21
Genetics of enzymatic dysfunctions in metabolic disorders and cancer
Mahé, M., Rios-Fuller, T. J., Karolin, A., & Schneider, R. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1230934 · Cited by 23
Complex role of HIF in cancer: the known, the unknown, and the unexpected
Huang, E. L., Tiburcio, P. D. B., & Choi, H. (2014) · Hypoxia · doi:10.2147/hp.s50651 · Cited by 20
Guo, X., Li, D., Wu, Y., Chen, Y., Zhou, X., Wang, X., Huang, X., Li, X., Yang, H., & Xing, J. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.12.005 · Cited by 23
Kong, H., Lee, S., Beebe, K. E., Scroggins, B. T., Gupta, G. N., Lee, M.-J., Jung, Y., Trepel, J. B., & Neckers, L. Μ. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.066514 · Cited by 20
Self-citationMitochondrial metabolic remodeling in response to genetic and environmental perturbations
Hollinshead, K. E. R., & Tennant, D. A. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1334 · Cited by 22
SALIDO, E. C., Timson, D. J., Betancor-Fernández, I., Palomino‐Morales, R., Anoz‐Carbonell, E., Pacheco‐García, J. L., Medina, M., & Pey, A. L. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050747 · Cited by 22
Mutational analysis of hypoxia‐related genes HIF1α and CUL2 in common human cancers
Park, S. W., Chung, N. G., Hur, S. Y., Kim, H. S., Yoo, N. J., & Lee, S. H. (2009) · Apmis · doi:10.1111/j.1600-0463.2009.02550.x · Cited by 21
Self-citationZhou, S., Liu, R. R., Yuan, K., Yi, T., Zhao, X., Huang, C., & Wei, Y. (2012) · Mass Spectrometry Reviews · doi:10.1002/mas.21362 · Cited by 21
Fumarate hydratase as a therapeutic target in renal cancer
Kancherla, P., Daneshvar, M., Sager, R., Mollapour, M., & Bratslavsky, G. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1804862 · Cited by 20
Châtre, L., Ducat, A., Spradley, F. T., Palei, A. C., Chéreau, C., Couderc, B., Thomas, K. C., Wilson, A. R., Amaral, L. M., Gaillard, I., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102406 · Cited by 21
MET as a Target in Papillary Renal Cell Carcinoma
Fay, A. P., Signoretti, S., & Choueiri, T. K. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0690 · Cited by 20
Review article: How cells sense oxygen: Lessons from and for the kidney
Gleadle, J. (2009) · Nephrology · doi:10.1111/j.1440-1797.2008.01064.x · Cited by 18
Zhunussova, A., Sen, B., Friedman, L., Tuleukhanov, S. T., Brooks, A. D., Sensenig, R., & Orynbayeva, Z. (2015) · Europe PMC (PubMed Central) · Cited by 20
Genetic basis of kidney cancer: a model for developing molecular‐targeted therapies
Vira, M. A., Novakovic, K. R., Pinto, P. A., & Linehan, W. M. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.06814.x · Cited by 20
Self-citationRao, Q., Xia, Q., Liang Cheng, C., & Zhou, X. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.1000-9604.2016.01.03 · Cited by 19
Discovery of post-translational modifications in immunometabolism by chemical proteomics
Zhang, Y., Qin, W., & Wang, C. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.09.013 · Cited by 19
Metabolic Rewiring in Radiation Oncology Toward Improving the Therapeutic Ratio
van Gisbergen, M. W., Zwilling, E., & Dubois, L. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.653621 · Cited by 20
Wang, Z., Chen, X., Fan, S., Zhu, C., Deng, H., Tang, J., Sun, X., Jia, S., Liao, Q., Xiao, W., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102633 · Cited by 19
Steensel, M. A. M. V., van Geel, M., Badeloe, S., Poblete‐Gutiérrez, P., & Frank, J. (2009) · Experimental Dermatology · doi:10.1111/j.1600-0625.2008.00808.x · Cited by 19
Wilms tumour as a possible early manifestation of hereditary leiomyomatosis and renal cell cancer?
Badeloe, S., van Spaendonck‐Zwarts, K. Y., Steensel, M. A. M. V., Marion, A. M. W. V., van Essen, A. J., Jonkman, M. F., Steijlen, P. M., Poblete‐Gutiérrez, P., van Geel, M., & Frank, J. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.09000.x · Cited by 19
Heritable Cancer Syndromes Related to the Hypoxia Pathway
Henegan, J. C., & Gómez, C. R. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00068 · Cited by 21
Metabolic regulations of a decoction of Hedyotis diffusa in acute liver injury of mouse models
Dai, M., Wang, F., Zou, Z., Xiao, G., Chen, H., & Yang, H. (2017) · Chinese Medicine · doi:10.1186/s13020-017-0159-4 · Cited by 19
VDACs Post-Translational Modifications Discovery by Mass Spectrometry: Impact on Their Hub Function
Pittalà, M. G. G., Nibali, S. C., Reina, S., Cunsolo, V., Francesco, A. D., Pinto, V. D., Messina, A. A., Foti, S., & Saletti, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312833 · Cited by 19
Modular Synthesis of Cell-Permeating 2-Ketoglutarate Esters
Zengeya, T. T., Kulkarni, R. A., & Meier, J. L. (2015) · Organic Letters · doi:10.1021/acs.orglett.5b00737 · Cited by 19
Zhang, X., Zhao, J., Yin, X., Liang, J., Wang, Y., Zheng, L., Tan, P., Lin, Y., Xu, N., Zhu, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59513-8 · Cited by 18
Ricketts, C. J., Killian, J. K., Vocke, C. D., Wang, Y., Merino, M. J., Meltzer, P. S., & Linehan, W. M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0278108 · Cited by 18
Self-citationThe Interplay between Dysregulated Metabolism and Epigenetics in Cancer
Bassal, M. A. (2023) · Biomolecules · doi:10.3390/biom13060944 · Cited by 19
Arginine Expedites Erastin-Induced Ferroptosis through Fumarate
Guo, X., Guo, Y., Li, J., Liu, Q., & Wu, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914595 · Cited by 18
Wang, Y., Liu, B., Li, F., Zhang, Y., Gao, X., Wang, Y., & Zhou, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1274239 · Cited by 18
Rewiring of RNA methylation by the oncometabolite fumarate in renal cell carcinoma
Fitzsimmons, C. M., Mandler, M. D., Lunger, J. C., Chan, D., Maligireddy, S. S., Schmiechen, A. C., Gamage, S. T., Link, C. N., Jenkins, L. M. M., Chan, K. C., et al. (2024) · NAR Cancer · doi:10.1093/narcan/zcae004 · Cited by 18
Self-citationMultiple cutaneous and uterine leiomyomatosis syndrome: a review.
Choudhary, S., McLeod, M. P., Torchia, D., & Romanelli, P. (2013) · Europe PMC (PubMed Central) · Cited by 18
Multiple painful cutaneous nodules and renal mass
Rothman, A., Glenn, G. M., Choyke, L. T., Srinivasan, R., Linehan, W. M., & Cowen, E. W. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.06.026 · Cited by 18
Self-citationOxygen sensors as therapeutic targets in kidney disease
Haase, V. H. (2017) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2017.01.015 · Cited by 18
Laustsen, C., Nielsen, P. M., Qi, H., Løbner, M. H., Palmfeldt, J., & Bertelsen, L. B. (2020) · Scientific Reports · doi:10.1038/s41598-020-66265-6 · Cited by 18
Yonese, I., Ito, M., Takemura, K. N., Kamai, T., & Koga, F. (2020) · Journal of Kidney Cancer and VHL · doi:10.15586/jkcvhl.2020.148 · Cited by 18
Hoang, M., & Joseph, J. W. (2020) · Islets · doi:10.1080/19382014.2020.1802183 · Cited by 17
The non-canonical functions of HIF prolyl hydroxylases and their dual roles in cancer
Yu, M., Lun, J., Zhang, H., Zhu, L., Zhang, G., & Fang, J. S. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.105982 · Cited by 20
Molecular Genetics of Renal Cell Carcinoma: A Narrative Review Focused on Clinical Relevance
Millan, B., Loebach, L., Blachman-Braun, R., Patel, M. H., Saini, J., Linehan, W. M., & Ball, M. W. (2025) · Current Oncology · doi:10.3390/curroncol32060359 · Cited by 20
Self-citationSerum lipoprotein–derived fatty acids regulate hypoxia-inducible factor
Shao, W., Hwang, J., Liu, C., Mukhopadhyay, D., Zhao, S., Shen, M., Alpergin, E. S. S., Wolfgang, M. J., Farber, S. A., & Espenshade, P. J. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015238 · Cited by 17
Hypoxia signaling and oxygen metabolism in cardio-oncology
Baik, A. H. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2021.12.013 · Cited by 20
Disruption of sirtuin 7 in zebrafish facilitates hypoxia tolerance
Liao, Q., Zhu, C., Sun, X., Wang, Z., Chen, X., Deng, H., Tang, J., Jia, S., Liu, W., Xiao, W., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105074 · Cited by 17
Hyperpolarized [1,4‐13C]‐diethylsuccinate: a potential DNP substrate for in vivo metabolic imaging
Billingsley, K. L., Josan, S., Park, J. M., Tee, S. S., Spielman-Sun, E., Hurd, R. E., Mayer, D., & Spielman, D. M. (2014) · NMR in Biomedicine · doi:10.1002/nbm.3071 · Cited by 17
Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma
Flaherty, K. T., & Puzanov, I. J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.005 · Cited by 16
Hereditary Leiomyomatosis and Renal Cell Cancer
Hansen, A., Chayed, Z., Pallesen, K. A. U., Vasilescu, I., & Bygum, A. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3366 · Cited by 16
Intracellular Succinylation of 8-Chloroadenosine and Its Effect on Fumarate Levels
Dennison, J. B., Ayres, M., Kaluarachchi, K. K., Plunkett, W. K., & Gandhi, V. V. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.085803 · Cited by 17
The role of hypoxia inducible factor-1 in cell metabolism – a possible target in cancer therapy
Aiba, R. S. B., Dimova, E. Y., Görlach, A., & Kietzmann, T. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.4.583 · Cited by 17
A Phenotypic Perspective on Mammalian Oxygen Sensor Candidates
Baysal, B. E. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.024 · Cited by 17
Metabolic pathways in cancers: key targets and implications in cancer therapy
Vijayakumar, S. N., Sethuraman, S., & Krishnan, U. M. (2015) · RSC Advances · doi:10.1039/c5ra06505d · Cited by 16
A computational analysis of S-(2-succino)cysteine sites in proteins
Miglio, G., Sabatino, A., Veglia, E., Giraudo, M. T., Beccuti, M., & Cordero, F. (2015) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2015.11.003 · Cited by 16
Bulku, A., Weaver, T. M., & Berkmen, M. B. (2018) · The Open Biochemistry Journal · doi:10.2174/1874091x01812010001 · Cited by 16
Evolving Treatment Paradigms in Non-clear Cell Kidney Cancer
Vaishampayan, U. N. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0521-5 · Cited by 15
Novel Hereditary Forms of Pheochromocytomas and Paragangliomas
Dahia, P. L. M. (2013) · Frontiers of hormone research · doi:10.1159/000345671 · Cited by 16
Non-clear cell advanced kidney cancer
Sánchez, P., Calvo, E., & Durán, I. (2010) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000390767.85658.83 · Cited by 17
Metabolic evaluations of cancer metabolism by NMR ‐based stable isotope tracer methodologies
Tavares, L. C., Jarak, I., Nogueira, F. N., Oliveira, P. J., & Carvalho, R. A. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12358 · Cited by 16
Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction
Madala, H. R., Helenius, I. T., Zhou, W., Mills, E. L., Zhang, Y., Liu, Y., Metelo, A. M., Kelley, M. L., Punganuru, S. R., Kim, K. B., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0246 · Cited by 19
Hou, Y., He, Y., Wang, J., Zhou, Y., Ma, B., Li, X., Shi, L., & Zhang, Q. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117530 · Cited by 15
Metadata
- Authors
- Isaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M., Trepel, J., Zbar, B., Toro, J., Ratcliffe, P. J., Linehan, W. M., & Neckers, L.
- Affiliations
- National Institutes of Health (US)
- Pusan National University (KR)
- University of Oxford (GB)
- National Cancer Institute (US)
- St George's Hospital (GB)
- Corresponding author
- Neckers, Len
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2005-08
- Volume
- 8
- Issue
- 2
- Pages
- 143-153
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2059747280
- Semantic Scholar
- 6906ef0c1fe45571640c3c7a6b3c9c2d9a979a64
- Cited by
- 958
- References
- 63
- Citations by year
- 2026: 26 · 2025: 30 · 2024: 30 · 2023: 36 · 2022: 45 · 2021: 37 · 2020: 46 · 2019: 40 · 2018: 50 · 2017: 40 · 2016: 44 · 2015: 64 · 2014: 54 · 2013: 60 · 2012: 64
- FWCI
- 14.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- fumarate hydratase, hypoxia-inducible factor, fumarate, HIF prolyl hydroxylase, competitive inhibition, clear cell renal cell carcinoma, biallelic loss, cancer susceptibility, hypoxia
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Adult, Alleles, Carcinoma, Renal Cell, DNA-Binding Proteins, Female, Fumarate Hydratase, Fumarates, Humans, Ketoglutaric Acids, Kidney Neoplasms, Male, Middle Aged, Nuclear Proteins, Procollagen-Proline Dioxygenase, Syndrome, Transcription Factors, Up-Regulation, Gene Expression Regulation, Neoplastic, Leiomyomatosis, Basic Helix-Loop-Helix Proteins, Basic Helix-Loop-Helix Transcription Factors, Hypoxia-Inducible Factor 1, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
